GB2126479A - Pharmaceutical-compositions in inert carbon dioxide atmosphere - Google Patents
Pharmaceutical-compositions in inert carbon dioxide atmosphere Download PDFInfo
- Publication number
- GB2126479A GB2126479A GB08324133A GB8324133A GB2126479A GB 2126479 A GB2126479 A GB 2126479A GB 08324133 A GB08324133 A GB 08324133A GB 8324133 A GB8324133 A GB 8324133A GB 2126479 A GB2126479 A GB 2126479A
- Authority
- GB
- United Kingdom
- Prior art keywords
- carbon dioxide
- base
- composition according
- sodium carbonate
- antibiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
A solid pharmaceutical composition comprising one or more beta - lactam antibiotics in acid or amphoteric form in association with at least one physiologically acceptable base in the presence of a gaseous atmosphere containing a stabilising amount of carbon dioxide at a concentration greater than that of atmospheric air. The compositions exhibit enhanced stability. A preferred antibiotic for the compositions is ceftazidime or a hydrate thereof, and a preferred base is sodium carbonate or a mixture thereof with one or more other bases.
Description
SPECIFICATION
Pharmaceutical compositions
This invention concerns improvements in or relating to pharmaceutical compositions. In particular, the invention relates to pharmaceutical compositions containing fi-lactam antibiotics.
ss-Lactam antibiotics are often administered by injection as a solution in a sterile aqueous vehicle. The antibiotics are commonly amphoteric or acidic compounds which are relatively insoluble in water and are advantageously present in such solutions as water-soluble salts formed with bases, e.g. the sodium salts. It has been proposed to formulate ss-lactam antibiotics with a solid base such as sodium carbonate so that on dissolution in a sterile aqueous injection medium, a water-soluble salt is formed by reaction between the antibiotic and the base. This may be done for example, where no stable water-soluble physiologically acceptable salt of the antibiotic has been found.However, it has been found that even such formulations can be unstable on large scale handling and subsequent storage even with exclusion of oxygen by using an atmosphere of nitrogen.
We have now surprisingly found that the stability of solid compositions containing a fi-lactam antibiotic and a base can be significantly improved by formulating the compositions with an atmosphere containing carbon dioxide. A marked effect on stability can be observed even with gas mixtures, e.g. nitrogen, containing carbon dioxide at concentrations as low as 10% by volume or even less.
Thus, the invention provides a solid pharmaceutical composition comprising one or more ss- lactam antibiotics in acidic or amphoteric form in association with at least one physiologically acceptable base in the presence of a gaseous atmosphere containing a stabilising amount of carbon dioxide at a concentration greater than that of atmospheric air.
ss-Lactam antibiotics which may be incorporated into the compositions according to the invention include, for example, cephalosporin compounds such as cefamandole, cefazolin, cephalexin, cephaloglycin, cephalothin, cephapirin, cephradine, cefaclor, cefadroxil, cefoxitin, cefatrizine, cefazoflur, cefazedone, ceforanide, cefsulodin, ceftezole, cephacetrile, cephanone, cefuroxime, cephoxazole, cefroxadine, cefmetazole, cefonicid, cefoperazone, cefotiam, cefotaxime, cefmenoxime, ceftizoxime, ceftriaxone, cefodizime, cefotetan, lamoxactam, cephaloridine in the form of an acid addition salt, e.g. the hydronitrate, ceftazidime, (6R,7R)-3-acetoxymethyl-7 [(Z)-2-(fur-2-yl)-2-methoxyiminoacetamido]ceph-3-em-4-carboxylic acid, (6R,7R)-7-[(Z)-2-(2-ami nothiazol-4-yl)-2-cyclopropylmethoxyiminoacetamido]-3-( 1 -pyridiniummethyl)ceph-3-em-4-carboxylate, (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-cyclopropylmethoxyiminoacetamido]-3-carba- moyloxymethylceph-3-em-4-carboxylic acid, and (6 R, 7 R)-7-[(Z)-2-( 1 -carboxycyclobut- 1 -oxyim ino)-2-(fur-2-yl)acetamido]-3-carbamoyloxymethylceph-3-em-4-carboxylic acid; penicillins such as penicillin G, penicillin V, amoxycillin, ampicillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, methicillin, nafcillin, oxacillin, phenethicillin and ticarcillin; clavulanic acid; thienamycins such as N-formimidoylthienamycin; monocyclic p-lactams such as azthreonam; and mixtures thereof. Antibiotics such as ceftazidime which contain basic groups may also be in the form of their acid addition salts, e.g. the hydrochlorides. Compositions containing mixtures of antibiotics may for example contain two such antibiotics, such as a mixture of amoxycillin and clavulanic acid or of ampicillin and flucloxacillin.
The fi-lactam compounds will normally be present in a form capable of reacting with a base, i.e. in an acidic or amphoteric form, which may optionally be solvated e.g. hydrated. It will be appreciated that where compositions according to the invention contain more than one fi-lactam antibiotic it is possible that only one of the antibiotic compounds is in an acidic or amphoteric form.
ss-Lactam antibiotics which may be particularly preferred for formulating into compositions according to the invention include, for example, ceftazidime, cephaloridine hydronitrate, cefoperazone, cefotaxime, cefsulodin, cefmenoxime and penicillin V.
Bases which may be used in the compositions according to the invention include, for example, alkali metal carbonates such as sodium or potassium carbonate; alkali metal bicarbonates such as sodium bicarbonate; alkali metal or ammonium phosphates such as sodium phosphate; ammonium carbonate; guanidine carbonate; organic bases such as phenylethylbenzylamine, dibenzylethylenediamine, ethanolamine, diethanolamine, N-methylglucosamine, Nmethylglucamine, sodium glucinate, lysine, lysine acetate, tromethamine, guanidine and arginine; and mixtures thereof. In general, the base component preferably includes at least one base capable of reacting with carbon dioxide and water; thus, for example, a carbonate may react in this way to form a bicarbonate, or a strong organic base, such as arginine, may react to form a carbonate.
A preferred composition of the invention contains ceftazidime, which may advantageously be present in the form of a hydrate e.g. the crystalline pentahydrate described in British Patent
Specification No. 2063871, together with sodium carbonate, advantageously in an anhydrous form.
The ratio of base to fi-lactam antibiotic in the compositions of the invention is desirably in the range of (0.8 to 6.0) equivalents of base to one equivalent of antibiotic and preferably about 0.9 to 4.0:1. In some cases ratios of base to fi-lactam as low as 0.5 may be useful. As indicated above, a mixture of bases may be used in which one component is generally capable of reacting with carbon dioxide and water. It may thus be convenient to use mixtures of sodium carbonate and bicarbonate. In mixtures of bases the component capable of reacting with carbon dioxide and water is preferably present in an amount of at least 0.05 equivalents per equivalent of antibiotic.
The amount of carbon dioxide in the compositions according to the invention may vary over wide limits. When the carbon dioxide is present in an atmosphere comprising a mixture of gases e.g. with air, the level of carbon dioxide will, of course, be substantially higher than the concentration of 0.03% by volume normally found in air. Thus, the atmosphere preferably contains at least 1%, more preferably at least 4% by volume of carbon dioxide. In general, however, we have found that the greatest stabilising effect is achieved with concentrations of carbon dioxide greater than about 10% by volume. In practice, it may be convenient to use higher concentrations of carbon dioxide, such as 50% or greater e.g. about 90% by volume.
The amount of carbon dioxide present is preferably sufficient to combine together with the base with any water present. The presence of water may arise by adsorption from the atmosphere, abrasion of crystalline hydrates or as residual solvent from the production process.
The compositions according to the invention are preferably provided in sealed containers e.g.
ampoules or vials or bulk storage containers. Ampoules or vials are conveniently such as to provide a unit dose of the active ingredient e.g. for constitution with a sterile vehicle for injection, such as pyrogen-free water. The dosage units will generally contain conventional amounts of the antibiotic substance(s). For example, dosage units may conveniently contain 50 to 2000 mg of the active ingredient. The dosage of active ingredient employed for adult human treatment will preferably range from 500 to 6000 mg per day depending on the antibiotic used and the route and frequency of administration.
The invention also extends to mixtures of the components occurring during blending, handling and filling into sealed containers such as ampoules or vials.
The compositions according to the invention may be prepared by bringing at least one acidic or amphoteric fi-lactam antibiotic in solid form, at least one physiologically acceptable base in solid form and an atmosphere containing a stabilising amount of carbon dioxide at a concentration greater than that of atmospheric air into association. For example, the fi-lactam antibiotic and the base, both in particulate form, may be blended together in air to give a homogeneous particulate mixture which is then filled into appropriate containers which are subsequently purged with carbon dioxide or a gas mixture containing it. Alternatively, the solid components may be blended together in an atmosphere comprising carbon dioxide, and may if desired be subsequently filled into containers also in an atmosphere comprising carbon dioxide.
In a further method, one of the solid components is filled into the container, followed by filling with the other solid component without mixing (the so-called "double-filling" method), the two fillings optionally being effected in the presence of carbon dioxide. The containers may then, if necessary, be purged with carbon dioxide. It will be appreciated that the compositions prepared by this method will not comprise a homogeneous mixture of the solid components.
In a still further method, the containers may be filled with a solution of the base which is then dried, e.g. by freeze drying, before adding the active ingredient and purging with carbon dioxide. Alternatively, when the base to be used is sodium carbonate, the containers may be filled with sodium bicarbonate in dry form or in solution which is then heated to form solid sodium carbonate before adding the active ingredient and purging with the carbon dioxide.
When the compositions are in powder form, it will be appreciated that the carbon dioxide may be in the ineterstices between particles of the active ingredient and the base as well as in any headspace above the solid components.
The fi-lactam antibiotic and base starting materials are preferably substantially free from water, other than water of crystallisation.
As indicated above, we have found that the stability of fi-lactam antibiotic in the compositions of the invention may be surprisingly improved. For example, we have found that in storage tests at elevated temperatures, the rate of degradation of ceftazidime in compositions of the invention can be as little as a quarter of that of a blend in a vial with a nitrogen headspace.
The invention will now be illustrated in the following non-limiting Examples:
Example 1
Formula per blend
Ceftazidime pentahydrate 14.818 kg (on anhydrous basis)
Sodium carbonate (anhydrous) 1.725 kg
The ceftazidime pentahydrate was blended aseptically with the sodium carbonate in a powder mixer. Quantities of this blend equivalent to 250 mg anhydrous ceftazidime were filled into glass vials. In each case the vial headspace was purged with carbon dioxide and the vial was closed using a rubber plug and a metal overseal applied by crimping. All operations were performed under sterile conditions.
The product may be constituted shortly before administration by dissolving the powder in water for injections.
Example 2
Formula per blend
Ceftazidime pentahydrate 15.200 kg (on anhydrous basis)
Sodium carbonate (anhydrous) 1.7695 kg
The ceftazidime pentahydrate was blended aseptically with the sodium carbonate in a powder mixer with a blanket of sterile carbon dioxide. Quantities of this blend equivalent to 250 mg anhydrous ceftazidime were filled into glass vials. In each case the vial headspace was purged with carbon dioxide and the vial was closed using a rubber plug and a metal overseal applied by crimping.
The product may be constituted, shortly before administration by dissolving the powder in water for injections.
Example 3
Formula per vial
Ceftazidime pentahydrate 260mg (on an hydros basis)
Sodium carbonate (anhydrous) 30mg The ceftazidime pentahydrate and sodium carbonate were accurately weighed into a glass vial and the headspace purged with carbon dioxide. A rubber plug was then inserted and a metal overseal applied by crimping.
The product may be constituted shortly before administration by dissolving the powder in water for injections
Example 4
General Method
The antibiotic was blended with the base using in each case quantities given in Table 1.
Quantities of the blend equivalent to 250mg of the anhydrous antibiotic were filled into glass vials. In each case the vial headspace was purged with carbon dioxide. The vial was then closed using a rubber plug and a metal overseal applied by crimping.
Stable 1
Antibiotic Weight (g) Base Weight (g)
Ceftazidime 1 5 Sodium carbonate 1.500 pentahydrate
Cephaloridine 10 Sodium carbonate 1.61 hydronitrate
Cefoperazone 9 Sodium carbonate 0.89
Cefotaxime 7 Sodium carbonate 1.14
Cefsulodin 9 Sodium carbonate 1.08
Cefmenoxime 9 Sodium carbonate 1.49
Ceftazidime 10 Guanidine carbonate 1.70 pentahydrate
Cephalexin 1 5 Sodium carbonate 4.t3 Ampicilline trihydrate 10 Sodium carbonate 2.76
Cefuroxime 10 Sodium carbonate 1.75
Cephalothin 10 Sodium carbonate 1.60
Compound A 10 Sodium carbonate 1.49
Compound B+ 10 Sodium carbonate 2.27
Ceftazidime 10 Potassium carbonate 2.08 pentahydrate
Ceftazidime 15 Arginine 4.43 pentahydrate
Cephoxazole 10 Sodium carbonate 1.27
Ceftizoxime 9 Sodium carbonate 1.74
Penicillin V 10 Sodium carbonate 2.27 *Compound A-(6 R, 7 R)-3-acetoxymethyI-7-(Z)-2-(fur-2-yl)-2-methoxyiminoa- cetamidojceph-3-em-4-carboxylic acid.
+ Compound B-(6 R, 7 R)-7-[(Z)-2-( 1 -carboxycyclobut- 1 -oxyimino)-2-(fur-2-yl)acetamido]-3-carbamoyloxymethylceph-3-em,-4-carboxylic acid.
Example 5
A powder blend of ceftfazidime pentahydrate and anhydrous sodium carbonate in a weight ration of 10:1 was weighed into glass vials using a target fill weight of 1.333g. The headspace of each vial was purged with standard gas mixtures of carbon dioxide in nitrogen before being closed by using a rubber plug and a metal overseal applied by crimping. The gas mixtures consisted of 20, 10, 8, 6, 4 and 2%v/v carbon dioxide in nitrogen. Vials were also filled using 100% carbon dioxide.
Example 6
Formula per blend
Ceftazidime pentahydrate 1 975g Arginine 525g
Sodium carbonate anhydrous 19.73g
The ceftazidime pentahydrate was blended with the arginine and the sodium carbonate in a powder mixer. The blend was filled into glass vials, using a target fill weight of 773.mg per vial.
Then the vial headspace was purged with carbon dioxide and the vial closed using a rubber plug and a metal overseal applied by crimping.
The product was dissolved, as for administration, by the addition of 1.5ml Water for
Injections.
Example 7
Formula per vial
Ceftazidime pentahydrate 1.212g
Tromethamine Q.2790g Sodium carbonate anhydrous 0.01 21 g The ceftazidime pentahydrate, tromethamine and sodium carbonate were accurately weighed into a glass vial and the headspace purged with carbon dioxide. A rubber plug was then inserted and a metal overseal applied by crimping.
The product was dissolved, as for administration, by the addition of 3ml Water for Injections.
Example 8
Formula per vial (6 R, 7 R)-7[(Z)-2-(2-aminothiazol-4-yl)-2-cyclopropylmethoxyiminoacetamido] 3-( 1 -pyridinium- methyl)ceph-3-em 4-carboxylate, bishydrochloride 363mg
Sodium carbonate anhydrous 65.5mg The cephalosporin antibiotic and the sodium carbonate anhydrous were accurately weighed into a glass vial and the headspace was purged with carbon dioxide. A rubber plug was then inserted and a metal overseal applied by crimping.
Claims (11)
1. A solid pharmaceutical composition comprising one or more ss-lactam antibiotics in acidic or amphoteric form in association with at least one physiologically acceptable base in the presence of a gaseous atmosphere containing a stabilising amount of carbon dioxide at a concentration greater than that of atmospheric air.
2. A composition according to claim 1 wherein the atmosphere contains at least 1% by volume of carbon dioxide.
3. A composition according to claim 2 wherein the atmosphere contains at least 4% by volume of carbon dioxide.
4. A composition according to claim 3 wherein the atmosphere contains at least 10% by volume of carbon dioxide.
5. A composition according to any one of the preceding claims which contains from 0.8 to 6.0 equivalents of base to one equivalent of antibiotic.
6. A composition according to claim 5 which contains from 0.9 to 4 equivalents of base to one equivalent of antibiotic.
7. A composition according to any one of the preceding claims wherein the base is arginine or a mixture thereof with one or more other bases.
8. A composition according to any one of claims 1 to 6 wherein the base is a carbonate or a mixture thereof with one or more other bases.
9. A composition according to claim 8 wherein the carbonate is sodium carbonate.
1 0. A composition according to any one of the preceding claims wherein the ss-lactam antibiotic is ceftazidime or a hydrate thereof.
11. A process for the preparation of a composition according to claim 1 which comprises bringing at least one acidic amphoteric fi-lactam antibiotic in solid form, at least one physiologically acceptable base in solid form and a gaseous atmosphere containing a stabilising amount of carbon dioxide at a concentration greater than that of atmospheric air into association.
1 2. A method of stabilising a pharmaceutical composition containing one or more ss-lactam antibiotics in acidic or amphoteric form which comprises formulating said fi-lactam antibiotic(s) and at least one physiologically acceptable base with a gaseous atmosphere containing a stabilising amount of carbon dioxide at a concentration greater than that of atmospheric air.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08324133A GB2126479B (en) | 1982-09-10 | 1983-09-09 | Pharmaceutical compositions in inert carbon dioxide atmosphere |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8225853 | 1982-09-10 | ||
| GB08324133A GB2126479B (en) | 1982-09-10 | 1983-09-09 | Pharmaceutical compositions in inert carbon dioxide atmosphere |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB8324133D0 GB8324133D0 (en) | 1983-10-12 |
| GB2126479A true GB2126479A (en) | 1984-03-28 |
| GB2126479B GB2126479B (en) | 1986-04-03 |
Family
ID=10532830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB08324133A Expired GB2126479B (en) | 1982-09-10 | 1983-09-09 | Pharmaceutical compositions in inert carbon dioxide atmosphere |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US4582830A (en) |
| JP (1) | JPS5973518A (en) |
| KR (1) | KR880001094B1 (en) |
| AT (1) | AT388671B (en) |
| AU (1) | AU566245B2 (en) |
| BE (1) | BE897721A (en) |
| CA (1) | CA1215647A (en) |
| CH (1) | CH655008A5 (en) |
| DE (1) | DE3332616C2 (en) |
| DK (1) | DK161304C (en) |
| ES (1) | ES525492A0 (en) |
| FR (1) | FR2532849B1 (en) |
| GB (1) | GB2126479B (en) |
| IE (1) | IE55720B1 (en) |
| IT (1) | IT1197708B (en) |
| NL (1) | NL189948C (en) |
| NZ (1) | NZ205539A (en) |
| PT (1) | PT77323B (en) |
| SE (1) | SE464615B (en) |
| ZA (1) | ZA836703B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4626534A (en) * | 1984-07-23 | 1986-12-02 | Eli Lilly And Company | Pharmaceutical formulation |
| WO1988009173A1 (en) * | 1987-05-27 | 1988-12-01 | Akzo N.V. | DRY, RAPIDLY SOLUBLE, COMPOSITIONS OF beta-LACTAM ANTIBIOTICS |
| AT393452B (en) * | 1985-08-05 | 1991-10-25 | Bristol Myers Squibb Co | Process for the preparation of a cephalosporin product for producing an injection solution |
| WO1999062559A1 (en) * | 1998-05-29 | 1999-12-09 | Bernard Charles Sherman | Pharmaceutical tablets comprising cefuroxime axetil |
| EP1625859A1 (en) * | 2004-08-13 | 2006-02-15 | Access Group ApS | A process for the preparation of a package comprising a sterilised bulk of a substance, and a package comprising a sterilised bulk of a penicilin |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE61679B1 (en) * | 1987-08-10 | 1994-11-16 | Fujisawa Pharmaceutical Co | Water-soluble antibiotic composition and water-soluble salts of new cephem compounds |
| ATE195920T1 (en) * | 1994-12-08 | 2000-09-15 | Otsuka Pharma Co Ltd | METHOD FOR SUPPRESSING THE ADSORPTION OF SUBSTANCES FROM THE CONTAINER MATERIAL BY MEDICINAL PRODUCTS |
| HRP970281B1 (en) * | 1996-05-28 | 2002-04-30 | Merck & Co Inc | Carbapenem antibiotic, composition and method of preparation |
| EP1618894B1 (en) | 2003-04-28 | 2018-06-13 | Takeda Pharmaceutical Company Limited | Composition for injection |
| JP4700291B2 (en) * | 2003-04-28 | 2011-06-15 | 武田薬品工業株式会社 | Injectable composition |
| CN102920710B (en) * | 2012-11-16 | 2014-05-28 | 罗诚 | Medicinal composition of cefodizime compound |
| CN103432137B (en) * | 2013-08-28 | 2015-01-28 | 芦红代 | Medicinal composition of cefoxitin |
| CN113350511B (en) * | 2021-03-01 | 2024-01-02 | 郎俊娜 | Novel sterile powder filling mixed shielding gas for injection |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1276839A (en) * | 1968-08-02 | 1972-06-07 | Sandoz Products Ltd | Antibiotic compositions |
| GB1300998A (en) * | 1969-05-02 | 1972-12-29 | Biochemie Gmbh | Improvements in or relating to effervescent antibiotic compositions |
| GB1380741A (en) * | 1971-02-05 | 1975-01-15 | Squibb & Sons Inc | Antibiotic compositions and their preparation |
| GB1435814A (en) * | 1972-08-18 | 1976-05-19 | Bocher D | Pharmaceutical compositions containing pyrrolidone-carboxylic acid or a derivative thereof |
| GB1463563A (en) * | 1974-10-10 | 1977-02-02 | Beecham Group Ltd | Pharmaceutical compositions |
| GB1499054A (en) * | 1975-04-09 | 1978-01-25 | Abbott Lab | Stable chelocardin composition |
| GB1536560A (en) * | 1974-12-31 | 1978-12-20 | Behringwerke Ag | Stable blood plasma process for preparing it and its use as comparative plasma in coagulation tests |
| GB2004182A (en) * | 1977-09-19 | 1979-03-28 | Lafon Labor | Process for preparing pharmaceutical cosmetic or diagnostic formulations |
| GB2006769A (en) * | 1977-10-10 | 1979-05-10 | Glaxo Group Ltd | -lactam compounds processes for their preparation pharmaceutical compositions containing them and intermediates of use in their preparation |
| EP0009845A1 (en) * | 1978-10-03 | 1980-04-16 | Gist-Brocades N.V. | Process for the manufacture of sodium amoxicillin preparations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB760087A (en) * | 1952-10-16 | 1956-10-31 | Novo Terapeutisk Labor As | Process of increasing the physical stability of aqueous suspensions of penicillin compounds |
| GB737242A (en) * | 1952-10-16 | 1955-09-21 | Novo Terapeutisk Labor As | Process of increasing the physical stability of aqueous suspensions of penicillin compounds |
| GB1132583A (en) * | 1964-12-16 | 1968-11-06 | Glaxo Lab Ltd | Pharmaceutical compositions containing cephalosporins |
| US3940483A (en) * | 1971-02-05 | 1976-02-24 | E. R. Squibb & Sons, Inc. | Antibiotic compositions and method |
| US4160829A (en) * | 1972-12-22 | 1979-07-10 | Gist-Brocades N.V. | Antibacterial 1,2,4-oxadiazolylacetamido cephalosporins |
| US3969524A (en) * | 1974-08-13 | 1976-07-13 | Hoffmann-La Roche Inc. | Stable amoxicillin dosage form |
| GB1575905A (en) * | 1976-04-28 | 1980-10-01 | Glaxo Lab Ltd | Salt of cefuroxime |
| GB1504767A (en) * | 1976-08-23 | 1978-03-22 | Beecham Group Ltd | Antibiotic compositions |
| JPS5329936A (en) * | 1976-08-31 | 1978-03-20 | Takeda Chem Ind Ltd | Antibiotic composition |
| AR228726A1 (en) * | 1978-05-26 | 1983-04-15 | Glaxo Group Ltd | PROCEDURE FOR THE PREPARATION OF ANTIBIOTIC (6R, 7R) -7 - ((Z) -2- (2-AMINOTIAZOL-4-IL) -2- (2-CARBOXIPROP-2-OXIIMINO) ACETAMIDO) -3- (1- PIRIDINIOMETIL) CEF-3-EM-4-CARBOXILATO |
| US4235900A (en) * | 1978-11-15 | 1980-11-25 | E. R. Squibb & Sons, Inc. | Cephradine compositions |
| FR2445833A1 (en) * | 1979-01-04 | 1980-08-01 | Chimie Biolog | Prepn. of water soluble salts of antibiotics - having a beta lactam ring, by treatment with sodium carbonate or bi:carbonate |
| US4329453A (en) * | 1979-10-02 | 1982-05-11 | Glaxo Group Limited | Cephalosporin antibiotic |
-
1983
- 1983-09-08 ES ES525492A patent/ES525492A0/en active Granted
- 1983-09-09 AT AT0322783A patent/AT388671B/en not_active IP Right Cessation
- 1983-09-09 FR FR8314396A patent/FR2532849B1/en not_active Expired
- 1983-09-09 CH CH4937/83A patent/CH655008A5/en not_active IP Right Cessation
- 1983-09-09 CA CA000436412A patent/CA1215647A/en not_active Expired
- 1983-09-09 KR KR1019830004246A patent/KR880001094B1/en not_active IP Right Cessation
- 1983-09-09 IE IE2118/83A patent/IE55720B1/en not_active IP Right Cessation
- 1983-09-09 US US06/530,655 patent/US4582830A/en not_active Expired - Lifetime
- 1983-09-09 BE BE0/211503A patent/BE897721A/en not_active IP Right Cessation
- 1983-09-09 PT PT77323A patent/PT77323B/en active IP Right Revival
- 1983-09-09 NZ NZ205539A patent/NZ205539A/en unknown
- 1983-09-09 NL NLAANVRAGE8303125,A patent/NL189948C/en not_active IP Right Cessation
- 1983-09-09 JP JP58165286A patent/JPS5973518A/en active Granted
- 1983-09-09 DK DK409183A patent/DK161304C/en not_active IP Right Cessation
- 1983-09-09 IT IT48950/83A patent/IT1197708B/en active Protection Beyond IP Right Term
- 1983-09-09 DE DE3332616A patent/DE3332616C2/en not_active Expired - Lifetime
- 1983-09-09 GB GB08324133A patent/GB2126479B/en not_active Expired
- 1983-09-09 AU AU18975/83A patent/AU566245B2/en not_active Expired
- 1983-09-09 ZA ZA836703A patent/ZA836703B/en unknown
- 1983-09-09 SE SE8304857A patent/SE464615B/en not_active IP Right Cessation
-
1987
- 1987-06-04 US US07/058,119 patent/US4803196A/en not_active Expired - Lifetime
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1276839A (en) * | 1968-08-02 | 1972-06-07 | Sandoz Products Ltd | Antibiotic compositions |
| GB1300998A (en) * | 1969-05-02 | 1972-12-29 | Biochemie Gmbh | Improvements in or relating to effervescent antibiotic compositions |
| GB1380741A (en) * | 1971-02-05 | 1975-01-15 | Squibb & Sons Inc | Antibiotic compositions and their preparation |
| GB1435814A (en) * | 1972-08-18 | 1976-05-19 | Bocher D | Pharmaceutical compositions containing pyrrolidone-carboxylic acid or a derivative thereof |
| GB1463563A (en) * | 1974-10-10 | 1977-02-02 | Beecham Group Ltd | Pharmaceutical compositions |
| GB1536560A (en) * | 1974-12-31 | 1978-12-20 | Behringwerke Ag | Stable blood plasma process for preparing it and its use as comparative plasma in coagulation tests |
| GB1499054A (en) * | 1975-04-09 | 1978-01-25 | Abbott Lab | Stable chelocardin composition |
| GB2004182A (en) * | 1977-09-19 | 1979-03-28 | Lafon Labor | Process for preparing pharmaceutical cosmetic or diagnostic formulations |
| GB2006769A (en) * | 1977-10-10 | 1979-05-10 | Glaxo Group Ltd | -lactam compounds processes for their preparation pharmaceutical compositions containing them and intermediates of use in their preparation |
| EP0009845A1 (en) * | 1978-10-03 | 1980-04-16 | Gist-Brocades N.V. | Process for the manufacture of sodium amoxicillin preparations |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4626534A (en) * | 1984-07-23 | 1986-12-02 | Eli Lilly And Company | Pharmaceutical formulation |
| AT393452B (en) * | 1985-08-05 | 1991-10-25 | Bristol Myers Squibb Co | Process for the preparation of a cephalosporin product for producing an injection solution |
| WO1988009173A1 (en) * | 1987-05-27 | 1988-12-01 | Akzo N.V. | DRY, RAPIDLY SOLUBLE, COMPOSITIONS OF beta-LACTAM ANTIBIOTICS |
| EP0293975A1 (en) * | 1987-05-27 | 1988-12-07 | Akzo N.V. | Dry, rapidly soluble, compositions of beta-lactam antibiotics |
| AU607784B2 (en) * | 1987-05-27 | 1991-03-14 | Akzo N.V. | Dry, rapidly soluble, compositions of beta-lactam antibiotics |
| WO1999062559A1 (en) * | 1998-05-29 | 1999-12-09 | Bernard Charles Sherman | Pharmaceutical tablets comprising cefuroxime axetil |
| EP1625859A1 (en) * | 2004-08-13 | 2006-02-15 | Access Group ApS | A process for the preparation of a package comprising a sterilised bulk of a substance, and a package comprising a sterilised bulk of a penicilin |
| WO2006015603A1 (en) * | 2004-08-13 | 2006-02-16 | Access Group Aps | A process for the preparation of a package comprising a sterilised bulk of a drug substance, and a package comprising a sterilised bulk ofa penicillin |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4582830A (en) | Pharmaceutical compositions | |
| CA2597812A1 (en) | Parenteral combination therapy for infective conditions with drug resistant bacterium | |
| RU2007124325A (en) | COMPOSITIONS FOR OVERCOMING MEDIATED BETA-LACTAMASE RESISTANCE TO ANTIBIOTICS USING A BETA-LACTAMASE INHIBITOR FOR THE INJECTION | |
| CA1056729A (en) | Injectable amoxycillin composition | |
| JPH10500975A (en) | Injectable preparation containing desiccant | |
| EP0029668B1 (en) | Pharmaceutical injectable composition and two-pack container for said composition | |
| KR19980075408A (en) | Method for stabilizing pharmaceutical compositions containing β-lactam antibiotics | |
| JP2761005B2 (en) | Injectable composition containing cephalosporin | |
| EP0052962B1 (en) | Pharmaceutical compositions containing two beta-lactam derivatives | |
| EP0008905B1 (en) | Pharmaceutical compositions containing two beta-lactam derivatives | |
| EP0008525A2 (en) | Pharmaceutical compositions and process for their preparation | |
| EP0221699B1 (en) | Composition for the treatment of infections | |
| EP0843552A2 (en) | Pharmaceutical formulations | |
| JPH02124822A (en) | Cephalosporin-containing composition for injection | |
| JPWO2009075309A1 (en) | Formulation composition | |
| KR19990001504A (en) | Injectables containing organic alkali salts of ceftazidime | |
| KR100396464B1 (en) | Stabilizing methods of pharmaceutical compositions containing a sodium salt of cefuroxime | |
| JPH02279627A (en) | Antibacterial composition | |
| GB2087721A (en) | Injectable antibiotic formulations stabilised with glycofurol | |
| JPH0446123A (en) | Production of aspirin dl-lysine injection | |
| JPS63174928A (en) | Pharmaceutical for injection | |
| JPH04247030A (en) | Antimicrobial composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE20 | Patent expired after termination of 20 years |